Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

NCT02441283 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02441283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02441283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Lead sponsor
AbbVie
Phase
Phase 2/3
Overall status
Completed
Start date
June 22, 2015
Completion date
October 15, 2019
Enrollment
384 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c